Clinical Trials Logo

Filter by:
NCT ID: NCT05447702 Recruiting - Clinical trials for Triple Negative Breast Cancer

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).

NCT ID: NCT05447572 Recruiting - Ulcerative Colitis Clinical Trials

FIT Combining FC for Predicting MH and Histology Remission in UC

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

Investigaters will perform a clinical trial to asess the abilitiy of qFIT and FC on predicting UC MH and histology remission.

NCT ID: NCT05447494 Recruiting - Clinical trials for Gaucher Disease, Type 1

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Start date: July 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Gaucher disease is a rare lysosomal storage disorder caused by deficient activity of the enzyme acid β-glucosidase, causing glucosylceramide to accumulate within macrophages and leading to hepatosplenomegaly, anemia, thrombocytopenia, and bone disease. In the non-neuronpathic form (type 1), disease manifestations are mostly systemic, whereas in the neuronopathic forms, glucosylceramide also accumulates in the central nervous sysem and leads to acute (type 2) or chronic (type 3) neurodegeneration. The purpose of this Phase 1/2 first-in-human study is to initially evaluate the safety and tolerability of two doses of CAN103, and then barring any safety concerns, to evaluate the efficacy and safety of the two doses administered intravenously every other week in treatment-naive subjects with Gaucher disease type 1 or type 3.

NCT ID: NCT05447260 Recruiting - Myelofibrosis Clinical Trials

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Start date: June 10, 2022
Phase: Phase 4
Study type: Interventional

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

NCT ID: NCT05447247 Recruiting - Clinical trials for To Investigate the Clinical Effect of Acupuncturing Ba Liao for Neurogenic Bladder Under the Guidance of Ultrasound

Clinical Study on Treatment of Neurogenic Bladder by Electroacupuncture on Ba Liao Point Under Ultrasound Guidance

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To explore acupuncture under the premise of real-time, dynamic and accurate positioning of Ba liao point with ultrasound, observe the clinical efficacy of treating neurogenic bladder, clarify the essence of acupoints, and provide a new method for the standardization of acupuncture and moxibustion.

NCT ID: NCT05447221 Recruiting - Gastric Cancer Clinical Trials

Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System

Start date: August 1, 2022
Phase:
Study type: Observational

The OLGIM staging system is highly recommended for a comprehensive assessment of GIM severity to evaluate patients' gastric cancer risk. However, its need to take at least 4 biopsies is not clinically feasible due to a serious shortage of pathologists compared with the large number of gastric cancer screening population. We plan to develop a Digital Pathology artificial intelligence diagnosis system (DPAIDS), to automatically identify tumor areas in whole slide images(WSI) and quickly and accurately quantify the severity of intestinal metaplasia according to the proportion of intestinal metaplasia areas.

NCT ID: NCT05447208 Recruiting - Growth Hormone Clinical Trials

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement. Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation. Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.

NCT ID: NCT05447195 Recruiting - Clinical trials for Newly-diagnosed Glioblastoma

Phase 2 Study of CAN008 in Subjects With GBM

Start date: October 10, 2021
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and after radiation therapy in newly-diagnosed subjects with glioblastoma who have undergone surgical excision.

NCT ID: NCT05447169 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Start date: July 10, 2022
Phase:
Study type: Observational

The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.

NCT ID: NCT05446935 Recruiting - Clinical trials for Thymic Epithelial Tumor

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence

CHOICE
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Hyperthermic intrathoracic chemotherapy (HITOC) offers an additional treatment option for malignant pleural tumors after surgical cytoreduction. Especially it is used to further improve local tumor control in thymic malignancies with pleural spread, who underwent multimodality therapy including surgical resection. A phase II clinical study was conducted to explore the efficacy and safety of surgery followed by HITOC (POD1: DOX, POD2: cisplatin) for thymic epithelial tumors with pleural spread or recurrence.